Reuters logo
BRIEF-Amgen announces positive results from planned overall survival analysis of phase 3 head-to-head ENDEAVOR trial
March 1, 2017 / 12:20 AM / 9 months ago

BRIEF-Amgen announces positive results from planned overall survival analysis of phase 3 head-to-head ENDEAVOR trial

Feb 28 (Reuters) - Amgen Inc :

* Announces positive results from planned overall survival analysis of phase 3 head-to-head ENDEAVOR trial

* Says study met the key secondary endpoint of OS

* Says phase 3 head-to-head trial showed Kyprolis significantly improved OS versus Velcade in relapsed/refractory multiple myeloma patients

* Says adverse events observed in the updated analysis consistent with those previously reported for ENDEAVOR

* Says plans to submit results to regulatory agencies worldwide to support potential label update to ENDEAVOR study results Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below